• Explore /
  • Poster
  • / MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway.

MEVITEM: A European, randomized, open-label Phase I/II of vismodegib in combination with temozolomide versus temozolomide alone in adult patients with recurrent/ refractory medulloblastoma presenting an activation of the Sonic Hedgehog pathway.

Abstract Poster

Authors

null

Didier Frappaz

Centre Léon Bérard, Lyon, France

Didier Frappaz , Olivier L. Chinot , David Meyronet , Gwenaelle Garin , Florence Laigle-Donadey , Emilie Le Rhun , Alice bonneville - Levard , Jean-Sebastien Frenel , Ahmed Idbaih , Carole Gourmelon , Krisztian Homisco , Andreas Hottinger , Emilie Remir , Laure Jaouen , Carole Arbault , Claire Cropet , David Pérol

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT02029001

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS2083)

DOI

10.1200/JCO.2016.34.15_suppl.TPS2083

Abstract #

TPS2083

Poster Bd #

267b

Abstract Disclosures

Similar Posters

First Author: Amar J. Gajjar

First Author: D. J. Cohen

First Author: Anne S. Tsao

First Author: Benjamin Adam Weinberg